Crinetics Pharmaceuticals (CRNX) Misses Q1 EPS by 11c
Tweet
Share
E-mailGet Alerts CRNX Hot Sheet
Join SI Premium – FREE
Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q1 EPS of ($1.04), $0.11 worse than the analyst estimate of ($0.93). Revenue for the quarter came in at $360 thousand versus the consensus estimate of $137.5 thousand.
For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Netflix climbs following Ackman stake, up 1.8%
- Legence Corp. (LGN) Misses Q2 EPS by 58c
- Pyxis Oncology, Inc. (PYXS) Misses Q2 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
